Daily Brief Health Care: Maze Therapeutics, D.Western Therapeutics Institute Inc., Ainos and more

In today’s briefing:

Maze Therapeutics Inc. (MAZE): Phase 2 Biopharma Targeting Kidney Disease Files for IPO.
4576 JP – Announced Revisions to FY24/12 Earnings Forecasts
Ainos, Inc: Previewing the Year Ahead with Focus on AI Nose Programs

Maze Therapeutics Inc. (MAZE): Phase 2 Biopharma Targeting Kidney Disease Files for IPO.

Currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease
Lead candidate initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose their first patient in the first quarter of 2025
We anticipate this company to set terms (share size, price range) in the next week for a late January / early February debut.

In light of recent performance trends, DWTI has revised its initial earnings forecasts announced on February 9, 2024.
In addition, the Company is recording an extraordinary loss in its non-consolidated financial results for the fiscal year ending December 2024.
Net sales are expected to increase due to strong royalty income from ophthalmic surgical aid “DW-1002” in Europe, the United States, etc.

Looking ahead in 2025, we expect greater visibility in Ainos’ AI Nose programs, including robotics, smart manufacturing, elderly care monitoring, and Ainos Flora for women’s health testing.
Veldona clinical trials in Sjogren’s syndrome and HIV-related oral warts remain on track, with Taiwan study completions expected in 2026.
Sets eye on robotics. Ainos aims to expand its AI Nose application to robotics. It is seeking collaboration with the robotics and humanoid developers, as it believes now is the time to equip robotics with the ability to smell, filling a key gap in robot sensory capabilities.

💡 Before it’s here, it’s on Smartkarma

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network